Clinically, SRC‐1 is frequently overexpressed in human CRC, which is positively correlated with PD‐L1 expression, but inversely correlated with the number of tumor‐infiltrating CD8+ T cells, implicating that targeting SRC‐1 may improve antitumor immunity. Here, CD8A is linked to neoplasm.